论文部分内容阅读
目的观察并分析吉非替尼一线治疗非小细胞肺癌的临床疗效以及安全性。方法选取我院经病理学或细胞学检查确诊的24例非小细胞肺癌患者,应用吉非替尼口服250mg,1次/d,坚持治疗直至肿瘤有所进展或者是出现严重的不良反应。结果 24例病例中完全缓解(CR)为0,部分缓解(PR)为50%,有效率为50%,疾病稳定(SD)为25%(6/24);疾病控制率是%,疾病进展(PD)为25%(6/24)。与药物相关的不良反应主要为皮疹和腹泻。结论吉非替尼一线治疗非小细胞肺癌的临床疗效较好,能够明显有效改善症状,减轻毒副作用,从而提高生活质量。
Objective To observe and analyze the clinical efficacy and safety of first-line gefitinib in the treatment of non-small cell lung cancer. Methods Twenty-four non-small cell lung cancer patients diagnosed by pathology or cytology in our hospital were treated with gefitinib orally 250mg once daily until the tumor progressed or there was a serious adverse reaction. Results The complete remission (CR) was 0, the partial response (PR) was 50%, the effective rate was 50%, the stable disease (SD) was 25% (6/24) in 24 patients; the disease control rate was%, the disease progressed (PD) was 25% (6/24). The main drug-related adverse reactions were rash and diarrhea. Conclusion The first-line gefitinib treatment of non-small cell lung cancer clinical efficacy is good, can effectively improve the symptoms, reduce side effects, thereby enhancing the quality of life.